PUBLISHED 11 September 2023 First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared…...
Introducing Our 2020-2021 VCRC-VF Fellow: Kinanah Yaseen, MD
Kinanah Yaseen, MD, was awarded the 2020 Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship. She is currently a junior faculty member in the Department of Rheumatic and Immunologic Diseases at Cleveland Clinic. Her interests involve all forms of vasculitis, especially small vessel vasculitis including granulomatosis with polyangiitis (GPA), microscopic…...
Upstate New York Physician Receives Honorable Mention in the Vasculitis Foundation’s 2021 V-RED Award Program
(May 2021) Scott Beegle, MD, has received an honorable mention in the Vasculitis Foundation’s (VFs) 2021 Recognizing Excellence in Diagnostics (V-RED) award program. Now in its eighth year, V-RED has grown into a powerful awareness campaign that recognizes medical providers worldwide for making a critical, early diagnosis of vasculitis. Mary…...
Recruiting: Efficacy and Safety of Benralizumab in EGPA compared to Mepolizumab (MANDARA)
Brief Summary: This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive…...
- 1
- 2
